Inovio Pharmaceuticals
10480 Wateridge Circle
San Diego
California
92121
United States
Tel: 858-597-6006
Website: http://www.inovio.com/
138 articles with Inovio Pharmaceuticals
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Pennsylvania-based Inovio said the regulatory agency has additional questions about the Phase II/III trial regarding the vaccine candidate itself, known as INO-4800, as well as the company’s Cellectra 2000 delivery device.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
-
Inovio’s development issues for its vaccine candidate have become mired in a conflict with the contract manufacturing organization it has worked with on previous projects.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
-
May 2020 Deadline Approaching for Inovio Pharmaceuticals (INO) Class Action
5/5/2020
Sokolove Law announces an investigation into a securities class action lawsuit filed against Inovio Pharmaceuticals (NASDAQ: INO) on behalf of shareholders. INO investors that purchased 20,000 shares or more between February 14 to March 9, 2020 and are interested in learning more about the class action lawsuit should call 800-974-3478 to explore their legal rights
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
-
INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
4/15/2020
INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means
-
Clinical Catch-Up: April 6-10
4/13/2020
It was a very busy week for clinical trial news. Here’s a look. -
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
4/12/2020
Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
-
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
4/6/2020
- Up to 40 Healthy Volunteers To Participate at Two Trial Locations - Preclinical Animal Studies Show Promising Immune Responses - Rapid Advancement Possible Through a Global Coalition of Collaborators, Partners, and Funders
-
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
3/30/2020
- VGX-3100 DNA medicine reduced qualifying high-risk HPV 16/18-associated precancerous vulvar lesion area in 80% of patients (by 60% on average); completely curing vulvar dysplasia with no virus detectable in 20% of patients - Data to be presented at the 2020 American Society for Colposcopy and Cervical Pathology (ASCCP) meeting [30-March-2020] PLYMOUTH MEETIN
-
INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia
3/26/2020
- VGX-3100 DNA medicine cleared high-risk HPV 16/18-associated precancerous lesions in 50% of patients, and reduced the number of lesions in 75% of patients - Data to be presented at the 2020 American Society for Colposcopy and Cervical Pathology (ASCCP) meeting [26-March-2020] PLYMOUTH MEETING, Pa. , March 26, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, In
-
Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
3/24/2020
Ology Bioservices Inc. and Inovio Pharmaceuticals Inc. announced that the Department of Defense has awarded Ology Bioservices with a contract valued at $11.9 million to work with Inovio on DNA technology transfer to rapidly manufacture DNA vaccines.
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.